Discover our innovative ADC pipeline
Let’s build tomorrow’s first- and best-in-class ADCs
We’re developing fit-for-purpose antibody-drug conjugates through a tailored “Trifecta” approach: strategic target selection, innovative proprietary MultiLINK™ linker technology, and smart payload choices. We’re looking to partner with biotechs and pharma companies to build potential game-changing ADC technologies.
Let's explore the potential of new generation of ADCs together
Get to know our strong in-house capabilities and in-depth expertise spanning ADC conjugation and optimization, pharmacokinetics/ pharmacodynamics, toxicology, translational, pharmaceutical, clinical development, and supply chain management.
Our pipeline of 1st- and best-in-class ADCs
Advantages of MultiLINK™ Linker Technology
-
High Stability - Maintains integrity in circulation
-
High DAR - Delivers more potency per antibody without aggregation
-
Versatility - Compatible with a wide range of antibodies and payloads
Reach out to discuss a feasibility study
We have a growing pipeline of projects in development in the areas of oncology, infectious disease, and conjugation technologies
Over the years, we’ve been developing Antibody Drug Conjugates while establishing our own proprietary linker technology
We scout for new, innovative pharmaceutical drug candidates to go through our full drug development value chain, from preclinical to registration
We are looking for out-licensing partners for all projects with a focus on our clinically advanced candidates